{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:08:03Z","timestamp":1785802083311,"version":"3.56.0"},"reference-count":104,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>There has been an increased interest in cell based therapies for a range of medical conditions in the last decade. This explosion in novel therapeutics research has led to the development of legislation specifically focused on cell and gene based therapies. In Europe, the European medicines agency (EMA) designates any medicines for human use which are based on genes, tissues, or cells as advanced therapy medicinal products or advanced therapy medicinal products (ATMPs). In this article we discuss the hurdles to widespread adoption of ATMPs in Europe, with a focus on regulatory T cells (Tregs). There are numerous barriers which must be overcome before mainstream adoption of Treg therapy becomes a reality. The source of the cells, whether to use autologous or allogenic cells, and the methods through which they are isolated and expanded, must all meet strict good manufacturing practice (GMP) standards to allow use of the products in humans. GMP compliance is costly, with the equipment and reagents providing a significant cost barrier and requiring specialized facilities and personnel. Conforming to the regulations set centrally by the EMA is difficult, and the different interpretations of the regulations across the various member states further complicates the regulatory approval process. The end products then require a complex and robust distribution network to ensure timely delivery of potentially life saving treatments to patients. In a European market whose logistics networks have been hammered by COVID and Brexit, ensuring rapid and reliable delivery systems is a more complex task than ever. In this article we will examine the impact of these barriers on the development and adoption of Tregs in Europe, and potential approaches which could facilitate more widespread use of Tregs, instead of its current concentration in a few very specialized centers.<\/jats:p>","DOI":"10.3389\/fmed.2023.1090721","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:20:07Z","timestamp":1674112807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Barriers to Treg therapy in Europe: From production to regulation"],"prefix":"10.3389","volume":"10","author":[{"given":"Conor","family":"Hennessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Deptula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Hester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"key":"B1","year":"2016","journal-title":"Achieving Large-Scale, Cost-Effective, Reproducible Manufacturing of High-Quality Cells: a Technology Road Map to 2025."},{"key":"B2","doi-asserted-by":"publisher","first-page":"19078","DOI":"10.1073\/pnas.0907396106","article-title":"Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis.","volume":"106","author":"Wright","year":"2009","journal-title":"Proc Natl Acad Sci."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040314","article-title":"Adoptive transfer of induced-treg cells effectively attenuates murine airway allergic inflammation.","volume":"7","author":"Xu","year":"2012","journal-title":"PLoS One."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/TP.0b013e3181ff8772","article-title":"Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanised mouse model.","volume":"90","author":"Issa","year":"2010","journal-title":"Transplantation."},{"key":"B5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells.","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol Orlando Fla."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics.","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation.","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1053\/j.gastro.2012.07.116","article-title":"Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn\u2019s disease.","volume":"143","author":"Desreumaux","year":"2012","journal-title":"Gastroenterology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","article-title":"Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.","volume":"153","author":"Marek-Trzonkowska","year":"2014","journal-title":"Clin Immunol Orlando Fla."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad4134","article-title":"Type 1 diabetes immunotherapy using polyclonal regulatory T cells.","volume":"7","author":"Bluestone","year":"2015","journal-title":"Sci Transl Med."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901273","article-title":"Dampened inflammatory signalling and myeloid-derived suppressor-like cell accumulation reduces circulating monocytic HLA-DR density and associates with malignancy risk in long-term renal transplant recipients.","volume":"13","author":"Bottomley","year":"2022","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015552","article-title":"Regulatory T-cell therapy in transplantation: moving to the clinic.","volume":"3","author":"Tang","year":"2013","journal-title":"Cold Spring Harb Perspect Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants.","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants.","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(20)30167-7","article-title":"Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1\/2A trials.","volume":"395","author":"Sawitzki","year":"2020","journal-title":"Lancet Lond Engl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/ajt.16395","article-title":"Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.","volume":"21","author":"Harden","year":"2021","journal-title":"Am J Transplant."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061864","article-title":"Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.","volume":"12","author":"Brook","year":"2022","journal-title":"BMJ Open."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ph14121321","article-title":"Quality assessment of investigational medicinal products in COVID-19 clinical trials: one year of activity at the clinical trials office.","volume":"14","author":"Dri","year":"2021","journal-title":"Pharmaceuticals."},{"key":"B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives.","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect.","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1182\/blood-2014-10-603449","article-title":"Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo.","volume":"125","author":"Parmar","year":"2015","journal-title":"Blood."},{"key":"B22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jcyt.2013.07.009","article-title":"Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease.","volume":"16","author":"Parmar","year":"2014","journal-title":"Cytotherapy."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611638","article-title":"Super-treg: toward a new era of adoptive treg therapy enabled by genetic modifications.","volume":"11","author":"Amini","year":"2021","journal-title":"Front Immunol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac078","article-title":"Regulatory T-cell therapy approaches.","author":"McCallion","year":"2022","journal-title":"Clin Exp Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.4049\/jimmunol.1302847","article-title":"Regulation of MHC class I expression by Foxp3 and its effect on Treg cell function.","volume":"192","author":"Mu","year":"2014","journal-title":"J Immunol Baltim Md 1950."},{"key":"B26","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.jcyt.2020.03.264","article-title":"Allogeneic CAR T-cells resistant to both T- and NK-cell cytotoxicity.","volume":"22","author":"Poirot","year":"2020","journal-title":"Cytotherapy."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","article-title":"Targeted disruption of the \u03b22-microglobulin gene minimizes the immunogenicity of human embryonic stem cells.","volume":"4","author":"Wang","year":"2015","journal-title":"Stem Cells Transl Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell."},{"key":"B29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.3860","article-title":"HLA-E-expressing pluripotent stem cells escape allogeneic responses and lysis by NK cells.","volume":"35","author":"Gornalusse","year":"2017","journal-title":"Nat Biotechnol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients.","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat Biotechnol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"p. 205","DOI":"10.1007\/978-1-0716-2647-4_14","article-title":"A GMP protocol for the manufacture of tregs for clinical application.","author":"O\u2019Neil","year":"2023","journal-title":"Regulatory T-Cells: Methods and Protocols. Methods in Molecular Biology."},{"key":"B32","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa7721","article-title":"Hurdles in therapy with regulatory T cells.","volume":"7","author":"Trzonkowski","year":"2015","journal-title":"Sci Transl Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.12112","article-title":"Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials.","volume":"173","author":"Berglund","year":"2013","journal-title":"Clin Exp Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2005.02.018","article-title":"Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+ CD25+ T cells.","volume":"115","author":"Baecher-Allan","year":"2005","journal-title":"Clin Immunol Orlando Fla."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/eji.201970107","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition).","volume":"49","author":"Cossarizza","year":"2019","journal-title":"Eur J Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/146532402317251608","article-title":"Cell sorting for therapeutic applications - points to consider.","volume":"4","author":"Gee","year":"2002","journal-title":"Cytotherapy."},{"key":"B38","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cyto.b.20111","article-title":"Sterile and disposable fluidic subsystem suitable for clinical high speed fluorescence-activated cell sorting.","author":"Jayasinghe","year":"2006","journal-title":"Cytometry B Clin Cytom."},{"key":"B39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/146532402317251590","article-title":"Public Meeting and Workshop on \u201cSafety issues pertaining to the clinical application of flow cytometry to human-derived cells.\u201d.","volume":"4","author":"Keane-Moore","year":"2002","journal-title":"Cytotherapy."},{"key":"B40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1080\/14653240701466321","article-title":"Modification of a commercial cell sorter to support efficient and reliable preparation of ALDH-bright cells for clinical use.","volume":"9","author":"Hickerson","year":"2007","journal-title":"Cytotherapy."},{"key":"B41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/gutjnl-2014-306919","article-title":"Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn\u2019s disease.","volume":"65","author":"Canavan","year":"2016","journal-title":"Gut."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00358-x","article-title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation.","author":"Proics","year":"2022","journal-title":"Gene Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.jcyt.2014.05.016","article-title":"Purification of regulatory T cells with the use of a fully enclosed high-speed microfluidic system.","volume":"16","author":"Hulspas","year":"2014","journal-title":"Cytotherapy."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00252","article-title":"Clinical grade regulatory CD4+ T Cells (Tregs): moving toward cellular-based immunomodulatory therapies.","volume":"9","author":"Duggleby","year":"2018","journal-title":"Front Immunol."},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003161","article-title":"Clinical grade treg: GMP isolation, improvement of purity by CD127pos depletion, treg expansion, and treg cryopreservation.","volume":"3","author":"Peters","year":"2008","journal-title":"PLoS One."},{"key":"B46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jim.2009.06.001","article-title":"Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation.","volume":"347","author":"Elkord","year":"2009","journal-title":"J Immunol Methods."},{"key":"B47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cyto.b.20621","article-title":"Cryopreservation modulates the detection of regulatory T cell markers.","author":"Sattui","year":"2012","journal-title":"Cytometry B Clin Cytom."},{"key":"B48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jim.2009.11.012","article-title":"Cryopreservation does not alter the frequency of regulatory T cells in peripheral blood mononuclear cells.","volume":"353","author":"Van Hemelen","year":"2010","journal-title":"J Immunol Methods."},{"key":"B49","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jim.2010.02.005","article-title":"Percentage of regulatory T cells CD4+CD25+CD127- in HIV-infected patients is not reduced after cryopreservation.","volume":"357","author":"Venet","year":"2010","journal-title":"J Immunol Methods."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.750286","article-title":"Freezing medium containing 5% DMSO enhances the cell viability and recovery rate after cryopreservation of regulatory T cell products ex vivo and in vivo.","volume":"9","author":"Kaiser","year":"2021","journal-title":"Front Cell Dev Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"9728","DOI":"10.18632\/oncotarget.23887","article-title":"Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype.","volume":"9","author":"Go\u0142\u0105b","year":"2018","journal-title":"Oncotarget."},{"key":"B52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.omtm.2018.01.006","article-title":"A rapamycin-based GMP-compatible process for the isolation and expansion of regulatory T cells for clinical trials.","volume":"8","author":"Fraser","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","article-title":"Expression of a chimeric antigen receptor specific for donor HLA Class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection.","volume":"17","author":"Boardman","year":"2017","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg."},{"key":"B54","doi-asserted-by":"publisher","first-page":"8209","DOI":"10.4049\/jimmunol.181.12.8209","article-title":"Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease.","volume":"181","author":"Huter","year":"2008","journal-title":"J Immunol Baltim Md 1950."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577186","article-title":"Autoantigen specific IL-2 activated CD4+CD25+T regulatory cells inhibit induction of experimental autoimmune neuritis.","volume":"341","author":"Tran","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/eji.200839073","article-title":"Curing CNS autoimmune disease with myelin-reactive Foxp3+ Treg.","volume":"39","author":"Stephens","year":"2009","journal-title":"Eur J Immunol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1084\/jem.20040139","article-title":"In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes.","volume":"199","author":"Tang","year":"2004","journal-title":"J Exp Med."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","article-title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.","volume":"126","author":"MacDonald","year":"2016","journal-title":"J Clin Invest."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123672","article-title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells.","volume":"4","author":"Dawson","year":"2019","journal-title":"JCI Insight."},{"key":"B60","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.4049\/jimmunol.1102661","article-title":"The role of naive T cell precursor frequency and recruitment in dictating immune response magnitude.","volume":"188","author":"Jenkins","year":"2012","journal-title":"J Immunol Baltim Md 1950."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.11.009","article-title":"Single-cell genomics unveils critical regulators of Th17 cell pathogenicity.","volume":"163","author":"Gaublomme","year":"2015","journal-title":"Cell."},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.10.068","article-title":"CD5L\/AIM regulates lipid biosythesis and restrains Th17 cell pathogenicity.","volume":"163","author":"Wang","year":"2015","journal-title":"Cell."},{"key":"B63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nri.2015.18","article-title":"Harnessing the plasticity of CD4+ T cells to treat immune-mediated disease.","volume":"16","author":"DuPage","year":"2016","journal-title":"Nat Rev Immunol."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.6873","article-title":"CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1\u03b1 and IP-10 are expressed in demyelinating brain lesions.","volume":"96","author":"Balashov","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"B65","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.4049\/jimmunol.171.12.6838","article-title":"Among CXCR3 Chemokines, IFN-\u03b3-Inducible Protein of 10 kDa (CXC Chemokine Ligand (CXCL) 10) but Not Monokine Induced by IFN-\u03b3 (CXCL9) Imprints a Pattern for the Subsequent Development of Autoimmune Disease.","volume":"171","author":"Christen","year":"2003","journal-title":"J Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/cmi.2015.12","article-title":"Regulatory T cells turn pathogenic.","volume":"12","author":"Guo","year":"2015","journal-title":"Cell Mol Immunol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00921","article-title":"Regulatory framework for advanced therapy medicinal products in Europe and United States.","volume":"10","author":"Iglesias-Lopez","year":"2019","journal-title":"Front Pharmacol."},{"key":"B68","year":"2020","journal-title":"Orphan designation: Overview."},{"key":"B69","year":"2013","journal-title":"Rules and Regulations Federal Register Internet."},{"key":"B70","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU Regulatory Pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation.","volume":"13","author":"Detela","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B71","year":"2021","journal-title":"Advanced Therapies: Marketing Authorisation."},{"key":"B72","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.omtm.2018.10.003","article-title":"Challenges in advanced therapy medicinal product development: a survey among companies in Europe.","volume":"11","author":"Ten Ham","year":"2018","journal-title":"Mol Ther Methods Clin Dev."},{"key":"B73","year":"2022","journal-title":"Regulation 2020\/1043 - Conduct of Clinical Trials with and Supply of Medicinal Products for Human use Containing or Consisting of Genetically Modified Organisms Intended to Treat or Prevent Coronavirus Disease (COVID-19) - EU monitor."},{"key":"B74","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1089\/hum.2021.058","article-title":"Call for more effective regulation of clinical trials with advanced therapy medicinal products consisting of or containing genetically modified organisms in the European Union.","volume":"32","author":"Beattie","year":"2021","journal-title":"Hum Gene Ther."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.757647","article-title":"Advanced therapy medicinal products\u2019 translation in Europe: a developers\u2019 perspective.","volume":"9","author":"Pizevska","year":"2022","journal-title":"Front Med."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00316-1","article-title":"A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada.","volume":"6","author":"Regier","year":"2022","journal-title":"NPJ Precis Oncol."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1017\/S026646232000063X","article-title":"Real-world evidence to support Payer\/HTA decisions about highly innovative technologies in the EU-actions for stakeholders.","author":"Facey","year":"2020","journal-title":"Int J Technol Assess Health Care."},{"key":"B78","first-page":"56","article-title":"UK at the forefront of advanced therapies.","volume":"26","author":"Bell","year":"2021","journal-title":"Eur Pharm Rev."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30327-9","article-title":"UK to align with EU clinical trial rules post-Brexit.","volume":"19","author":"Burki","year":"2018","journal-title":"Lancet Oncol."},{"key":"B80","year":"1991","journal-title":"Commission Directive 91\/356\/EEC of 13 June 1991 Laying Down the Principles and Guidelines of Good Manufacturing Practice for Medicinal Products for Human Use."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jcyt.2016.05.012","article-title":"Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow-derived multipotent mesenchymal stromal cells.","volume":"18","author":"Codinach","year":"2016","journal-title":"Cytotherapy."},{"key":"B82","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.jcyt.2016.02.010","article-title":"Hurdles in clinical implementation of academic advanced therapy medicinal products: a national evaluation.","volume":"18","author":"de Wilde","year":"2016","journal-title":"Cytotherapy."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00012","article-title":"Advanced therapy medicinal products and exemptions to the regulation 1394\/2007: how confident can we be? An exploratory analysis.","volume":"3","author":"Van Wilder","year":"2012","journal-title":"Front Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40259-013-0020-y","article-title":"Development and regulation of biosimilars: current status and future challenges.","volume":"27","author":"Tsiftsoglou","year":"2013","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther."},{"key":"B85","year":"2022","journal-title":"Final Report Summary - AGORA (ATMP GMP Open Access Research Alliance - AGORA) | FP7 | CORDIS |."},{"key":"B86","year":"2020","journal-title":"Evaluate Pharma World Preview 2020, Outlook to 2026."},{"key":"B87","year":"2021","journal-title":"Opportunities and challenges for Cell Gene Therapies in Pharmaceuticals and Medical Products in Europe."},{"key":"B88","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jcyt.2021.12.012","article-title":"Impact considerations of post-production processes on cell and gene drug products.","volume":"24","author":"Fink","year":"2022","journal-title":"Cytotherapy."},{"key":"B89","year":"2020","journal-title":"C19 and Cell and Gene Therapy."},{"key":"B90","year":"2022","journal-title":"Tomorrows Supply Chain: Disruption around every Corner."},{"key":"B91","year":"2022","journal-title":"CAT-Quarterly-Highlights-Approved-Atmps."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1111\/bcp.14286","article-title":"Managing access to advanced therapy medicinal products: challenges for NHS Wales.","volume":"87","author":"Champion","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means.","volume":"26","author":"McCabe","year":"2008","journal-title":"PharmacoEconomics."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-019-00871-9","article-title":"The new and non-transparent cancer drugs fund.","volume":"38","author":"Wood","year":"2020","journal-title":"PharmacoEconomics."},{"key":"B95","year":"2017","journal-title":"Interim Process and Methods of the Highly Specialised Technologies Programme Updated to reflect 2017 Changes."},{"key":"B96","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40273-016-0460-6","article-title":"Economic evaluations of pharmaceuticals granted a marketing authorisation without the results of randomised trials: a systematic review and taxonomy.","volume":"35","author":"Hatswell","year":"2017","journal-title":"PharmacoEconomics."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2017.1355203","article-title":"Annuity payments can increase patient access to innovative cell and gene therapies under England\u2019s net budget impact test.","volume":"5","author":"J\u00f8rgensen","year":"2017","journal-title":"J Mark Access Health Policy."},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1715536","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries.","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"J Mark Access Health Policy."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2019.1635842","article-title":"Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate.","volume":"7","author":"J\u00f8rgensen","year":"2019","journal-title":"J Mark Access Health Policy."},{"key":"B100","year":"2022","journal-title":"Major German Payers Sign Pay for Performance Agreements on CAR-Ts."},{"key":"B101","year":"2017","journal-title":"Novartis 2017 US Transparency and Patient Access Report."},{"key":"B102","year":"2019","journal-title":"Proposed Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2001259","article-title":"Accelerating translational research through open science: the neuro experiment.","volume":"14","author":"Gold","year":"2016","journal-title":"PLoS Biol."},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.respol.2021.104226","article-title":"The fall of the innovation empire and its possible rise through open science.","volume":"50","author":"Gold","year":"2021","journal-title":"Res Policy."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1090721\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T07:20:11Z","timestamp":1674112811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1090721\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":104,"alternative-id":["10.3389\/fmed.2023.1090721"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1090721","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]},"article-number":"1090721"}}